Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial

[1] Danforth E(2000)Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 26 13-1669

[2] Saltiel AR(1996)Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 45 1661-2104

[3] Olefsky JM(2004)A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors Arch Intern Med 164 2097-442

[4] Chiquette E(2015)Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 58 429-324

[5] Ramirez G(2016)Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis JAMA 316 313-281

[6] Defronzo R(2016)What can we learn from interventions that change fat distribution? Curr Obes Rep 5 271-2791

[7] Inzucchi SE(2002)Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 87 2784-514

[8] Bergenstal RM(2006)Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes Diabetes Care 29 510-3152

[9] Buse JB(2003)Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity Diabetes Care 26 3148-C1608

[10] Palmer SC(1993)Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells Am J Phys 264 C1600-1399

[1] Danforth E(2000)Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 26 13-1669

[2] Saltiel AR(1996)Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 45 1661-2104

[3] Olefsky JM(2004)A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors Arch Intern Med 164 2097-442

[4] Chiquette E(2015)Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 58 429-324

[5] Ramirez G(2016)Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis JAMA 316 313-281

[6] Defronzo R(2016)What can we learn from interventions that change fat distribution? Curr Obes Rep 5 271-2791

[7] Inzucchi SE(2002)Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 87 2784-514

[8] Bergenstal RM(2006)Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes Diabetes Care 29 510-3152

[9] Buse JB(2003)Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity Diabetes Care 26 3148-C1608

[10] Palmer SC(1993)Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells Am J Phys 264 C1600-1399